Anli Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anli Zhang has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Yang-Xin Fu
Changping Laboratory, Beijing, China
9 shared publications - Zhenhua Ren
Hunan Provincial Key Laboratory of Intelligent Disaster Prevention-Mitigation and Ecological Restoration in Civil Engineering, Hunan Institute of Engineering, Xiangtan 411104, China
6 shared publications Chuanhui Han
Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA
5 shared publicationsZhida Liu
Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA
4 shared publicationsChangzheng Lu
Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA
3 shared publicationsChunbo Dong
Department of Pathology, UT Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75390-9072, USA
3 shared publications
Latest Publications
- 9 October 2023
- Published by Elsevier in Cancer Cell
- Vol. 41 (10) , 1788-1802.e10
Systematic investigation of mitochondrial transfer between cancer cells and T cells at single-cell resolution
- 9 October 2023
- Published by Elsevier in Cancer Cell
- Vol. 41 (10) , 1788-1802.e10
Systematic investigation of mitochondrial transfer between cancer cells and T cells at single-cell resolution
- Open Access
- 15 March 2022
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (3) , 100554
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
- 15 March 2022
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (3) , 100554
Open AccessAXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
- Open Access
- 1 February 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (3)
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers. We fortuitously observed that anti–PD-1 therapy depends on IL-2 signaling, which raises the possibility that a lack of IL-2 limits anti–PD-1–induced effector T cell expansion. To selectively deliver IL-2 to PD-1+CD8+ tumor-infiltrating lymphocytes (TILs), we engineered a low-affinity IL-2 paired with anti–PD-1 (PD-1–laIL-2), which reduced affinity to peripheral Treg cells but enhanced avidity to PD-1+CD8+ TILs. PD-1–laIL-2 exerted better tumor control and lower toxicity than single or mixed treatments. Mechanistically, PD-1–laIL-2 could effectively expand dysfunctional and tumor-specific CD8+ T cells. Furthermore, we discovered that presumably dysfunctional PD-1+TIM3+ TILs are the dominant tumor-specific T cells responding to PD-1–laIL-2. Collectively, these results highlight that PD-1–laIL-2 can target and reactivate tumor-specific TILs for tumor regression as a unique strategy with stronger efficacy and lower toxicity.
- 1 February 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (3)
Open AccessSelective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers. We fortuitously observed that anti–PD-1 therapy depends on IL-2 signaling, which raises the possibility that a lack of IL-2 limits anti–PD-1–induced effector T cell expansion. To selectively deliver IL-2 to PD-1+CD8+ tumor-infiltrating lymphocytes (TILs), we engineered a low-affinity IL-2 paired with anti–PD-1 (PD-1–laIL-2), which reduced affinity to peripheral Treg cells but enhanced avidity to PD-1+CD8+ TILs. PD-1–laIL-2 exerted better tumor control and lower toxicity than single or mixed treatments. Mechanistically, PD-1–laIL-2 could effectively expand dysfunctional and tumor-specific CD8+ T cells. Furthermore, we discovered that presumably dysfunctional PD-1+TIM3+ TILs are the dominant tumor-specific T cells responding to PD-1–laIL-2. Collectively, these results highlight that PD-1–laIL-2 can target and reactivate tumor-specific TILs for tumor regression as a unique strategy with stronger efficacy and lower toxicity.
- 4 August 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (605)
Dual targeting of CTLA-4 and CD47 on T reg cells promotes immunity against solid tumors
Selective CD47 blockade on CTLA-4 high tumor-infiltrating T reg cells reduces systemic toxicity and enhances antitumor immunity.
- 4 August 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (605)
Dual targeting of CTLA-4 and CD47 on T reg cells promotes immunity against solid tumors
Selective CD47 blockade on CTLA-4 high tumor-infiltrating T reg cells reduces systemic toxicity and enhances antitumor immunity.
- 17 December 2020
- Published by Elsevier in Cancer Cell
- Vol. 39 (1) , 96-108.e6
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
- 17 December 2020
- Published by Elsevier in Cancer Cell
- Vol. 39 (1) , 96-108.e6
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
- 7 December 2020
- Published by Springer Nature in Oncogene
- Vol. 40 (5) , 885-898
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy
Recently, immune checkpoint blockade (ICB), especially anti-programmed death 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) therapy, has become an increasingly appealing therapeutic strategy for cancer patients. However, only a small portion of patients responds to anti-PD treatment. Therefore, treatment strategies are urgently needed to reverse the ICB-resistant tumor microenvironment (TME). It has become clear that the TME has diminished innate sensing that is critical to activate adaptive immunity. In addition, tumor cells upregulate various immunosuppressive factors to diminish the immune response and resist immunotherapy. In this review, we briefly update the current small molecular drugs that could synergize with immunotherapy, especially anti-PD therapy. We will discuss the modes of action by those drugs including inducing innate sensing and limiting immunosuppressive factors in the TME.
- 7 December 2020
- Published by Springer Nature in Oncogene
- Vol. 40 (5) , 885-898
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy
Recently, immune checkpoint blockade (ICB), especially anti-programmed death 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) therapy, has become an increasingly appealing therapeutic strategy for cancer patients. However, only a small portion of patients responds to anti-PD treatment. Therefore, treatment strategies are urgently needed to reverse the ICB-resistant tumor microenvironment (TME). It has become clear that the TME has diminished innate sensing that is critical to activate adaptive immunity. In addition, tumor cells upregulate various immunosuppressive factors to diminish the immune response and resist immunotherapy. In this review, we briefly update the current small molecular drugs that could synergize with immunotherapy, especially anti-PD therapy. We will discuss the modes of action by those drugs including inducing innate sensing and limiting immunosuppressive factors in the TME.
- Open Access
- 30 September 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-13
Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis
Effectively activating macrophages against cancer is promising but challenging. In particular, cancer cells express CD47, a ‘don’t eat me’ signal that interacts with signal regulatory protein alpha (SIRPα) on macrophages to prevent phagocytosis. Also, cancer cells secrete stimulating factors, which polarize tumor-associated macrophages from an antitumor M1 phenotype to a tumorigenic M2 phenotype. Here, we report that hybrid cell membrane nanovesicles (known as hNVs) displaying SIRPα variants with significantly increased affinity to CD47 and containing M2-to-M1 repolarization signals can disable both mechanisms. The hNVs block CD47-SIRPα signaling axis while promoting M2-to-M1 repolarization within tumor microenvironment, significantly preventing both local recurrence and distant metastasis in malignant melanoma models. Furthermore, by loading a stimulator of interferon genes (STING) agonist, hNVs lead to potent tumor inhibition in a poorly immunogenic triple negative breast cancer model. hNVs are safe, stable, drug loadable, and suitable for genetic editing. These properties, combined with the capabilities inherited from source cells, make hNVs an attractive immunotherapy.
- 30 September 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-13
Open AccessHybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis
Effectively activating macrophages against cancer is promising but challenging. In particular, cancer cells express CD47, a ‘don’t eat me’ signal that interacts with signal regulatory protein alpha (SIRPα) on macrophages to prevent phagocytosis. Also, cancer cells secrete stimulating factors, which polarize tumor-associated macrophages from an antitumor M1 phenotype to a tumorigenic M2 phenotype. Here, we report that hybrid cell membrane nanovesicles (known as hNVs) displaying SIRPα variants with significantly increased affinity to CD47 and containing M2-to-M1 repolarization signals can disable both mechanisms. The hNVs block CD47-SIRPα signaling axis while promoting M2-to-M1 repolarization within tumor microenvironment, significantly preventing both local recurrence and distant metastasis in malignant melanoma models. Furthermore, by loading a stimulator of interferon genes (STING) agonist, hNVs lead to potent tumor inhibition in a poorly immunogenic triple negative breast cancer model. hNVs are safe, stable, drug loadable, and suitable for genetic editing. These properties, combined with the capabilities inherited from source cells, make hNVs an attractive immunotherapy.
- 16 September 2020
- Published by Springer Nature in Nature Immunology
- Vol. 21 (11) , 1470
Author Correction: Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 16 September 2020
- Published by Springer Nature in Nature Immunology
- Vol. 21 (11) , 1470
Author Correction: Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 2 July 2020
- Published by Elsevier in Cancer Cell
- Vol. 38 (3) , 400-411.e6
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
- 2 July 2020
- Published by Elsevier in Cancer Cell
- Vol. 38 (3) , 400-411.e6
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
- 30 March 2020
- Published by Springer Nature in Nature Immunology
- Vol. 21 (5) , 546-554
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
High-dose radiation activates caspases in tumor cells to produce abundant DNA fragments for DNA sensing in antigen-presenting cells, but the intrinsic DNA sensing in tumor cells after radiation is rather limited. Here we demonstrate that irradiated tumor cells hijack caspase 9 signaling to suppress intrinsic DNA sensing. Instead of apoptotic genomic DNA, tumor-derived mitochondrial DNA triggers intrinsic DNA sensing. Specifically, loss of mitochondrial DNA sensing in Casp9−/− tumors abolishes the enhanced therapeutic effect of radiation. We demonstrated that combining emricasan, a pan-caspase inhibitor, with radiation generates synergistic therapeutic effects. Moreover, loss of CASP9 signaling in tumor cells led to adaptive resistance by upregulating programmed death-ligand 1 (PD-L1) and resulted in tumor relapse. Additional anti-PD-L1 blockade can further overcome this acquired immune resistance. Therefore, combining radiation with a caspase inhibitor and anti-PD-L1 can effectively control tumors by sequentially blocking both intrinsic and extrinsic inhibitory signaling.
- 30 March 2020
- Published by Springer Nature in Nature Immunology
- Vol. 21 (5) , 546-554
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
High-dose radiation activates caspases in tumor cells to produce abundant DNA fragments for DNA sensing in antigen-presenting cells, but the intrinsic DNA sensing in tumor cells after radiation is rather limited. Here we demonstrate that irradiated tumor cells hijack caspase 9 signaling to suppress intrinsic DNA sensing. Instead of apoptotic genomic DNA, tumor-derived mitochondrial DNA triggers intrinsic DNA sensing. Specifically, loss of mitochondrial DNA sensing in Casp9−/− tumors abolishes the enhanced therapeutic effect of radiation. We demonstrated that combining emricasan, a pan-caspase inhibitor, with radiation generates synergistic therapeutic effects. Moreover, loss of CASP9 signaling in tumor cells led to adaptive resistance by upregulating programmed death-ligand 1 (PD-L1) and resulted in tumor relapse. Additional anti-PD-L1 blockade can further overcome this acquired immune resistance. Therefore, combining radiation with a caspase inhibitor and anti-PD-L1 can effectively control tumors by sequentially blocking both intrinsic and extrinsic inhibitory signaling.